Atakan Tekinalp
Overview
Explore the profile of Atakan Tekinalp including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
16
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Goktas E, Zamani A, Yildirim M, Demircioglu S, Tekinalp A, Ceneli O
J Coll Physicians Surg Pak
. 2024 Nov;
34(11):1294-1298.
PMID: 39491447
Objective: To determine the coexistence of multiple PML-RARA transcripts in adult APL (acute promyelotic leukaemia) patients, and its impact on the patients' laboratory parameters, treatment responses, and prognoses. Study Design:...
2.
Mehtap O, Toptas T, Dal M, Keklik Karadag F, Atas U, Ozsan G, et al.
Leuk Lymphoma
. 2024 Sep;
65(14):2190-2198.
PMID: 39269267
Predictive prognostic scoring (PS) systems are not primarily applicable to elderly patients with classical Hodgkin lymphoma (cHL). The objective of this study was to develop a PS system for these...
3.
Ciftciler R, Selim C, Comert M, Zengin H, Ipek Y, Gursoy V, et al.
J Oncol Pharm Pract
. 2024 Sep;
:10781552241280615.
PMID: 39221456
Background And Aim: Chronic myeloid leukemia (CML) incidence has recently increased in younger individuals. With time, given the nature of the disease and available therapies, as well as the existing...
4.
Tekinalp A, Geduk A, Akdeniz A, Terzi Demirsoy E, Gursoy V, Aslaner Ak M, et al.
Turk J Haematol
. 2023 Nov;
40(4):242-250.
PMID: 37961952
Objective: This study aimed to evaluate patients with relapsed/refractory multiple myeloma (RRMM) who underwent daratumumab (DARA) therapy. Materials And Methods: This multicenter retrospective study included 134 patients who underwent at...
5.
Yilmaz S, Ceneli O, Tekinalp A
J Coll Physicians Surg Pak
. 2023 May;
33(5):539-543.
PMID: 37190689
Objective: To investigate the appropriateness of Bentley and plasmic scores and ADAMTS-13 activity to distinguish between primary thrombotic microangiopathies (TMA) syndromes and other thrombotic microangiopathies, as well as primary thrombotic...
6.
Ozatli D, Giden A, Erkurt M, Korkmaz S, Basci S, Ulas T, et al.
Transfus Apher Sci
. 2023 Feb;
62(2):103662.
PMID: 36842884
Therapeutic apheresis is an extracorporeal treatment that selectively removes abnormal cells or harmful substances in the blood that are associated with or cause certain diseases. During the last decades the...
7.
Kars T, Yorganci Z, Yaskiran O, Tekinalp A, Demircioglu S
J Oncol Pharm Pract
. 2022 Dec;
29(4):1011-1014.
PMID: 36458320
Introduction: Rituximab, which is widely used in the treatment of B-cell lymphoma, is a chimeric monoclonal antibody directed against the CD20 antigen. Rituximab has many side effects, mainly allergic and...
8.
Yesilaltay A, Degirmenci H, Bilgen T, Sirin D, Bayir D, Degirmenci P, et al.
Medicine (Baltimore)
. 2022 Aug;
101(32):e29881.
PMID: 35960118
Background: We have aimed at exposing left ventricular diastolic functions and the presence of known genetic mutations for familial erythrocytosis, in patients who exhibit idiopathic erythrocytosis. Methods: Sixty-four patients with...
9.
Demircioglu S, Tekinalp A, Ceneli O
J Coll Physicians Surg Pak
. 2022 Jan;
32(1):132-133.
PMID: 34983169
Null.
10.
Akpinar S, Dogu M, Celik S, Ekinci O, Hindilerden I, Dal M, et al.
Clin Lymphoma Myeloma Leuk
. 2021 Oct;
22(3):169-173.
PMID: 34629286
Introduction/background: The emergence of novel agents targeting the B-cell receptor pathway and BCL-2 has significantly changed the therapeutic landscape of CLL. We evaluated the safety and efficacy of single-agent ibrutinib...